Research and Development

Research and Development

Lymphact - Research and Development

Cellular Immunotherapy (CI) is designed to stimulate the cells of the immune system, the body’s natural mechanism to fight diseases. A CI consists of the adoptive transfer of ex vivo activated immune cells to cancer patients. These cellular therapy technologies were shown to overcome many limitations of current “standard-of-care” cancer treatments.

Our technology can generate several different types of cell therapy products. The first product is an autologous cellular immunotherapy. In this first product the immune cells (white blood cells) are first extracted from the peripheral blood of each patient (a common procedure called “leukapheresis”). These immune cells are then chemically treated and expanded using our proprietary technology and re-infused back in the same patient from whom they were collected from. In this context, the infused cells will be totally recognized as "self" by the patient's immune system, preventing graft rejection and consequent toxic side effects. Notwithstanding, recent scientific data suggests that our technology is safe enough to be used as allogeneic cell therapy, i.e., immune cells can be collected from healthy donors and infused in non-related cancer patients, an off-the-shelf solution.

Once inside the patient's body, the infused cells will directly bind to and kill cancer cells, treating the disease. Our solution selectively targets all non-healthy cells, including chemotherapy-resistant cancer stem cells and viral reservoirs, believed to cause cancer recurrence and opportunistic infections, respectively.

Of note, our T-cell immunotherapy product:

-can be produced for a lower cost than our main cell therapy competitors (no genetic manipulation);

-is simple and optimized for large-scale clinical applications;

-has broad application to several types of cancer sites.